Ligand Pharmaceuticals | LGND - Operating Profit

Stock Price
192.50
Daily Change
-5.83 -2.94%
Monthly
-1.80%
Yearly
63.36%
Q1 Forecast
186.18

Ligand Pharmaceuticals reported $158.89M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Amgen USD 3.96B 464M Dec/2025
Arrowhead Research USD 44.11M 209.66M Sep/2025
Baxter International USD 201.2M 70.8M Sep/2025
Bristol-Myers Squibb USD 3.64B 135M Sep/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Gilead Sciences USD 3.51B 810M Sep/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Glaxosmithkline GBP 3.76B 1.32B Sep/2025
Insmed USD -261.35M 7.48M Sep/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
Ligand Pharmaceuticals USD 158.89M 149.17M Sep/2025
MacroGenics USD 18.64M 55.4M Sep/2025
Merck USD 6.24B 318M Dec/2025
Pacira USD 13.15M 2.92M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Veracyte USD 23.11M 8.8M Sep/2025